Dr. Peihua Lu |Chairman of Beijing Ludaopei Biotech Co., Ltd. | Medical Director of Ludaopei Hospital | Director of Beijing Ludaopei Hematology Research Institute

Dr. Peihua Lu

Chairman of Beijing Ludaopei Biotech Co., Ltd. | Medical Director of Ludaopei Hospital | Director of Beijing Ludaopei Hematology Research Institute

Specialization:

• Allogeneic Hematopoietic Stem Cell Transplantation

• CAR-T Cell Therapy

• Hematology & Oncology

Biography

Dr. Peihua Lu is an internationally recognized hematologist and oncologist with extensive experience in stem cell transplantation and immunotherapy, including pioneering work with CAR-T cell therapy. After completing his medical education at Beijing Medical University, Dr. Lu moved to the United States where he obtained licensure in both hematology and oncology. He completed his clinical fellowship at Stanford University Medical Center, specializing in hematology and oncology.

Dr. Lu is a leading expert in the treatment of various hematological malignancies, including lymphoma, leukemia, and multiple myeloma, and is renowned for his work in hematopoietic stem cell transplantation and cellular immunotherapies. He has led several groundbreaking research studies, contributing to the development of advanced treatments for blood cancers, and is a key figure in the clinical application of CAR-T cell therapies.

Dr. Lu returned to China in 2015 and has since led significant advancements in hematology, particularly in the treatment of refractory cancers and rare blood diseases. He currently serves as the Medical Director of Ludaopei Hospital and the Director of the Beijing Ludaopei Hematology Research Institute.

Academic and Research Contributions

Dr. Lu has authored numerous influential research papers published in prestigious journals such as J. Immunol., Biol Blood Marrow Transplant, Leukemia, and Cancer. His research on cytokine-induced killer (CIK) cells and CAR-T cell therapy has been instrumental in advancing cellular immunotherapies, particularly for leukemia and lymphoma patients.

He has presented his research at major international conferences, including the American Society of Hematology (ASH), European Society for Blood and Marrow Transplantation (EBMT), and American Society of Clinical Oncology (ASCO). His work continues to shape the future of hematology and oncology treatment.

Awards and Recognition

• "2021 Medical Management Award" from the Medical Value Healthcare Taishan Award

• "2021 People’s Good Doctor of the Year"

• "2022 Most Beautiful Scientific Worker" in Sanhe City

Dr. Lu is also a distinguished member of numerous medical societies, including:

• Chairman of the Hematology and Stem Cell Transplantation Committee of the Chinese Private Medical Institutions Association

• Member of the Blood Cancer and Leukemia Alliance Expert Committee, Chinese Anti-Cancer Association

• Committee Member of the Clinical Hematology Branch of the Chinese Society of Clinical Oncology